Infliximab versus alpha interferon in the treatment of Beh'et's disease: the BIO BEH'ET'S RCT Infliximab versus alpha interferon in the treatment of Behçet's disease: the BIO BEHÇET'S RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National Institute for Health and Care Research Select
Infliximab for ICI induced enterocolitis (OW21) infliximab for ICI-induced enterocolitis - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * * All...Search All Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * Accessing medicinesShow Submenu For About usWho we areWhat we doOur committeesWho we work withOur researchOur reports and strategiesSustainabilityContact us More× * OW21 documents * NHS Wales * NHS 111 Wales * Accessibility * Contact us All...SearchPrint this page (expand headings to print hidden text)infliximab Status: Supported for use via the One Wales Medicines process Using the agreed starting and stopping criteria infliximab can
Infliximab - refractory pulmonary sarcoidosis Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 5 Infliximab for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosuppressants (OW23)February 2023 ONE WALES INTERIM DECISION Infliximab for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosuppressants Date of advice: February 2023 The following One Wales Medicines Assessment Group (OWMAG) recommendation has been endorsed by health board Chief Executives. Using the agreed starting and stopping criteria, infliximab can be made available within NHS Wales for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis Evidence summary Published: 24 February 2021 www.nice.org.uk/guidance/es35 pathwaysProduct overview Product overview The content of this evidence summary was up to date in February 2021. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Remsima for subcutaneous injection (Celltrion Healthcare Hungary) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)-alpha. It received
Infliximab - Remsima sc Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities View of Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities | Canadian Journal of Health TechnologiesReturn to Article DetailsInfliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities
Infliximab (Remsima SC) - ulcerative colitis View of Infliximab (Remsima SC) | Canadian Journal of Health TechnologiesReturn to Article DetailsInfliximab (Remsima SC)
Infliximab (Remsima SC) - Crohn's disease View of Infliximab (Remsima SC) | Canadian Journal of Health TechnologiesReturn to Article DetailsInfliximab (Remsima SC)
Infliximab (Remsima SC) - Crohn Disease and ulcerative colitis View of Infliximab (Remsima SC) | Canadian Journal of Health TechnologiesReturn to Article DetailsInfliximab (Remsima SC)
Subcutaneous infliximab biosimilar for treating inflammatory conditions Published: 13 September 2024 Driving Better Decision-Making in Healthcare Page 1 Subcutaneous infliximab biosimilar for treating inflammatory conditions Technology Guidance from the MOH Drug Advisory Committee Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended subcutaneous infliximab biosimilar (Remsima) for inclusion on the MOH List of Subsidised Drugs for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The decision was based on unacceptable pricing proposal from the company. Technology Guidance Driving Better Decision-Making in Healthcare Page 2 About the Agency The Agency for Care
Infliximab (Ixifi) - Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis or plaque psoriasis Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel
Ixifi (infliximab) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Evidence summary Published: 21 July 2020 www.nice.org.uk/guidance/es29 pathwaysProduct overview Product overview The content of this evidence summary was up-to-date in July 2020. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Remsima for subcutaneous injection (Celltrion Healthcare Hungary Kft) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)-alpha. It has a marketing authorisation for managing rheumatoid
Clinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis) Skip to main contentCookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work.We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose. Change my preferences I'm OK with analytics cookiesHome News Publications Statistics Blogs Events Contact usSearch SearchAbout us Our work Commissioning Get involved CoronavirusClinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis
Infliximab for Graft Versus Host Disease Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Infliximab for Graft Versus Host DiseaseCopied to clipboardInfliximab for Graft Versus Host Disease( Last Updated : May 11, 2022)Project Line:Reference ListProject Sub Line:Summary of AbstractsProject Number:RB1614-000DetailsQuestionWhat is the clinical effectiveness of infliximab in patients with graft versus host disease?Key MessageNo evidence was identified about the clinical effectiveness of infliximab in patients with graft versus host disease.FilesInfliximab for Graft Versus Host DiseaseBack to TopStay up to date on the latest from CADTH
Infliximab for Graft versus Host Disease Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Infliximab for Graft versus Host DiseaseCopied to clipboardInfliximab for Graft versus Host Disease( Last Updated : July 6, 2022)Project Line:Health Technology ReviewProject Sub Line:Summary of AbstractsProject Number:RB1621-000DetailsQuestionWhat are the benefits and harms of Infliximab for graft-versus-host disease?Key MessageThree non-randomized studies were found about the benefits and harms of Infliximab for graft-versus-host disease.FilesInfliximab for Graft versus Host DiseaseBack to TopStay up to date on the latest from CADTH, and subscribe
Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis * Homepage * Main navigation * Content area * Sitemap * SearchThe Federal Administration in treecrumb format * The federal Council * The federal Council admin.ch * FCh: Federal Chancellery * FDFA: Federal Archives * MeteoSwiss: Federal Office of Meteorology and Climatology * Swissmedic: Swiss Agency for Therapeutic Products * FOGE: Federal Office for Gender Equality * FOPH * FOPH: Federal Office of Public Health Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritisLanguages * DE * FR * IT * ENService
Infliximab (Avsola) Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More servicesYou are here: 1. HomeSummary Basis of Decision - - Health Canada * Drugs